Strumento inattivo

Altre lingue Xeris Biopharma Holdings, Inc. Nasdaq

Azioni

XERS

US98422L1070

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Xeris Biopharma Appoints John Shannon as CEO	08/07
Xeris Biopharma Announces CEO Succession Plan	08/07
Xeris Biopharma Holdings, Inc. Announces CEO Changes	08/07
Xeris Biopharma Holdings, Inc. Announces Executive Changes	08/07
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(4)	04/07
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	03/07
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024	03/06
Sector Update: Health Care Stocks Higher in Afternoon Trading	30/05
Xeris Biopharma Says Potential Levothyroxine Injection Preferred Over Oral Formulation; Shares Rise	30/05
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)	30/05
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)	30/05
Xeris to Participate in the Jefferies Global Healthcare Conference	30/05
Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M	09/05
Xeris Biopharma: Q1 Earnings Snapshot	09/05
Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events	09/05
Xeris Biopharma Holdings, Inc. Provides Revenue Guidance for the Full Year 2024	09/05
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Xeris Biopharma Collaborating With Beta Bionics for Development, Commercialization of Glucagon Product	06/05
Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics	06/05
Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024	02/05

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Xeris Biopharma Holdings, Inc. Nasdaq

Azioni

XERS

US98422L1070

Altre lingue

Filtri